Developer docs
API playgroundTry for free, no card

Search company profiles

Onc.AI

Full company profile

uuid0000pie

Namestring
Onc.AI
Legal namestring
Onc.Ai, Inc.
Websiteurl
onc.ai
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Onc.AI is a privately held digital health company founded in 2020 and headquartered in the San Francisco Bay Area with a distributed team including a Waterloo, Ontario presence. The company develops the Onclara™ platform, a deep-learning imaging AI system that ingests standard CT scans and automatically extracts clinically relevant radiomic biomarkers—including tumor intensity, texture and morphology features, multi-site tumor burden, vascular morphology, and body composition—without manual annotation. These biomarkers feed multiple AI products: Onclara™ Evaluate (Serial CTRS) for Phase IB/II oncology clinical trial decision-making and patient stratification, Onclara™ IO for predicting immunotherapy response and 12-month overall survival in PD-L1-High metastatic non-small cell lung cancer, Lung Clinical Management (LCM) for treatment decisions, and Onclara™ Studio for cloud-based cohort and patient-level visualization.

The company operates a dual-segment enterprise model targeting pharmaceutical companies for clinical trial licensing and risk-stratification services, and healthcare systems/oncology practices for clinical decision support once FDA clearance is secured. Onclara Evaluate has received FDA Breakthrough Device Designation and a planned 510(k) submission for Onclara IO is targeted for 2027. Validation partnerships span Pfizer, GSK, and Merck on the pharma side, with Flatiron Health as a real-world data partner and clinical collaborations across Stanford Medicine, City of Hope, MD Anderson, Emory Winship, Providence Health, Baylor Scott & White, and University of Rochester Medical Center. Revenue mechanics are primarily licensing/royalty-based for pharma trial applications, with a future subscription/recurring revenue stream anticipated for clinical decision support once FDA clearance is obtained. Pricing is not publicly disclosed and all products are currently investigational.

Onc.AI has raised approximately $33 million in total funding, including a $25 million Series A in January 2023 co-led by MassMutual and Action Potential Venture Capital and a $2 million NCI SBIR grant in October 2024. The leadership team is led by founders Akshay Nanduri (CEO) and Salmaan Ahmed (VP Software), with Lester Boeh as COO and Petr Jordan, PhD as CTO. The board is chaired by Jonathan Fleming and includes clinically credentialed directors and board observers, with a scientific and clinical advisory bench spanning oncology, immunotherapy, and AI/radiomics expertise. The company remains pre-commercial as of the most recent data, with revenue not publicly disclosed.

Short descriptiontext

Onc.AI is a clinical-stage digital health company that builds deep-learning imaging AI models applied to CT scans to predict immunotherapy response and support oncology clinical trial decisions, serving pharmaceutical companies and oncology practices with its Onclara platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Carlos, United States
HQ citystring
San Carlos
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology AI software, imaging biomarkers, clinical trial decision support, deep learning radiomics, immunotherapy response prediction
Industry3 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAKAFAL
Thoracic (Lung) Oncology
NAICS code2 codes
  • Medical and Diagnostic Laboratories6215
  • Custom Computer Programming Services541511
SIC code2 codes
  • Services-Medical Laboratories8071
  • Surgical & Medical Instruments & Apparatus3841
Product category
AI-Powered Clinical Decision Support for Oncology
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharma Clinical Trial Solutions
TypeLicensing Royalties
Description

Licensing or service fees from pharmaceutical companies for Onclara Evaluate to improve clinical trial design, patient stratification, and go/no-go decision-making in Phase IB and Phase II trials

onc.ai
2Clinical Decision Support
TypeSubscription Recurring
Description

Potential future revenue from healthcare systems for Onclara IO clinical decision support tools for metastatic lung cancer patients treated with immunotherapy

onc.ai
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Onclara™
Description

Market-leading oncology real-world dataset platform that trains predictive and prognostic AI models for clinical decision-making in cancer treatment.

onc.ai
+3 more records
Core offering1 text field

Onc.AI develops and sells the Onclara™ AI platform that applies deep learning to CT imaging to extract radiomic biomarkers and predict cancer treatment outcomes. Its core products include Onclara™ Evaluate for Phase IB/Phase II clinical trial decision-making (FDA Breakthrough designated) and Onclara™ IO for predicting response and outcomes in metastatic lung cancer patients receiving immunotherapy, sold to pharmaceutical companies and healthcare systems.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Onclara IO High patients achieved median overall survival of 484 days vs 155 days for Onclara IO Low patients in PD-L1-High metastatic NSCLC (validated on Flatiron Health data, n=205)
+2 more records
Product overview1 text field

Onc.AI offers the Onclara™ platform, a unified AI-powered system for oncology decision-making comprising multiple integrated products. The platform includes Onclara™ Evaluate (FDA Breakthrough designated) for clinical trial decision-making, Onclara™ IO for immunotherapy response prediction in metastatic lung cancer, Serial CTRS for NSCLC risk classification, and Lung Clinical Management for treatment decisions. Onclara™ Studio provides cloud-based visualization and analysis tools. The products leverage deep learning applied to CT imaging to extract radiomic biomarkers, tumor burden metrics, and body composition data to generate risk stratifications and survival predictions.

Product and service6 records
1Onclara Platform
CategoryAI Platform
Description

Core AI platform that leverages a market-leading oncology real-world dataset to train predictive and prognostic AI models for oncology clinical trials and clinical practice; provides the infrastructure for Onclara Evaluate, Onclara IO, Serial CTRS, LCM, and Onclara Studio.

2Onclara Evaluate
CategoryClinical Trial Decision Support Software
Description

AI-powered clinical decision support tool that improves Phase IB/Phase II clinical trial decision-making for pharmaceutical companies; uses deep learning to identify highest-risk patients and provide calibrated probability of achieving 12-month overall survival. FDA Breakthrough Device Designated. Sold to enterprise pharma companies.

3Onclara IO
CategoryClinical Decision Support Software
Description

AI-based CT imaging biomarker that predicts response and outcomes for metastatic lung cancer patients treated with immunotherapy; externally validated on Flatiron Health data for PD-L1-High metastatic non-small cell lung cancer. Targets healthcare systems and oncology clinical practice.

4Onclara Studio
CategoryCloud Analytics Platform
Description

Cloud-based platform providing intuitive visual and tabular outputs for immediate review or biostatistical analysis; supports secure CT scan upload and displays cohort-level analysis (Kaplan-Meier curves), patient-level tumor burden analysis, and body composition analysis. Sold to enterprise pharma companies and clinical users.

5Serial CTRS (Serial CT Response Score)
CategoryClinical Trial Decision Support Software
Description

Deep learning model that classifies non-small cell lung cancer patients into risk groups; outperforms RECIST 1.1 in predicting overall survival in metastatic NSCLC patients treated with PD-1 immunotherapy. FDA Breakthrough Device Designated. Sold to pharmaceutical companies for clinical trial applications.

6Lung Clinical Management (LCM)
CategoryClinical Decision Support Software
Description

AI-driven tool for informing treatment decision-making for metastatic lung cancer patients treated with immunotherapy; validated on Pfizer clinical trial data and real-world datasets. Targets oncologists and healthcare providers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical validation partner; Onc.AI models validated on Pfizer clinical trial data including LCM validation and Serial CTRS validation on Pfizer trials; ongoing collaboration for AI-driven clinical decision support

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical validation partner; Serial CTRS validated on GSK GARNET NSCLC cohort; collaboration for clinical development of AI biomarkers in oncology

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Pharmaceutical partner for clinical AI solutions and potential validation studies

Strategic tierCoreTypeTechnology or Integration
Description

Real-world data provider for external validation of Onc.AI models; provided retrospective cohort of 205 patients for Onclara IO validation; leading oncology data and analytics company

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical validation partner; LCM clinical utility retrospective chart review study

6Baylor Scott & White
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical partner for validation studies and real-world data collaboration

onc.ai
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical partner for validation studies and healthcare system collaboration

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical partner for validation studies; comprehensive cancer center

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical partner for validation studies; NCI-designated cancer center

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical partner for validation studies; NCI-designated cancer center

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical partner for validation studies and academic research collaboration

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medical imaging vendor with AI-augmented CT and radiology software portfolios. Broad incumbent competitor that distributes imaging AI through its installed CT base and enterprise imaging platform.

TypeOthers
Description

Oncology real-world data and EHR company (Roche subsidiary) and Onc.AI's external validation partner for Onclara IO. Comparable as an oncology data/AI ecosystem participant, though primarily an enabling data partner rather than a direct imaging-AI competitor.

TypeDirect peer
Description

AI-driven clinical decision support platform for genomic and imaging data used by hospitals and pharma. Comparable as a multimodal AI clinical decision support vendor serving both clinical practice and pharma/biotech.

TypeEmerging player
Description

AI-powered pathology platform supporting pharma biomarker development and clinical diagnostics. Comparable AI-for-oncology business model serving pharma R&D and clinical workflows, focused on pathology rather than radiology.

TypeDirect peer
Description

Provides imaging AI and radiomics solutions for oncology clinical trials and patient management. Closely comparable as an imaging-AI vendor targeting pharma trial design and oncology decision support.

TypeDirect peer
Description

AI biotech company building prognostic and predictive biomarkers from real-world patient data for pharma R&D and clinical decision support across oncology. Comparable business model of AI biomarkers sold into pharma and provider workflows.

TypeEmerging player
Description

AI for digital pathology in oncology, including FDA-authorized products. Comparable as an AI oncology company selling into pharma and pathology labs, but with a different primary modality (pathology vs CT imaging).

TypeDirect peer
Description

Develops AI-derived biomarkers from pathology and clinical data to personalize oncology treatment decisions, including for prostate cancer. Directly comparable as an AI biomarker company selling into both pharma clinical trials and clinical decision support.

TypeBroad incumbent
Description

Global medical imaging and diagnostics incumbent with growing AI/radiomics offerings embedded in CT and PACS workflows. A broader incumbent that can bundle competing imaging AI into its installed base.

10Tempus Labs
TypeBroad incumbent
Description

Large oncology AI and data platform combining molecular profiling, imaging, and clinical data to support pharma R&D and clinical decision support. Broader portfolio than Onc.AI but overlaps in AI-driven oncology decision-making.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Onc.AI

AI-Powered Clinical Decision Support for Oncologyonc.ai

Onc.AI is a clinical-stage digital health company that builds deep-learning imaging AI models applied to CT scans to predict immunotherapy response and support oncology clinical trial decisions, serving pharmaceutical companies and oncology practices with its Onclara platform.

What Onc.AI does

Onc.AI is a privately held digital health company founded in 2020 and headquartered in the San Francisco Bay Area with a distributed team including a Waterloo, Ontario presence. The company develops the Onclara™ platform, a deep-learning imaging AI system that ingests standard CT scans and automatically extracts clinically relevant radiomic biomarkers—including tumor intensity, texture and morphology features, multi-site tumor burden, vascular morphology, and body composition—without manual annotation. These biomarkers feed multiple AI products: Onclara™ Evaluate (Serial CTRS) for Phase IB/II oncology clinical trial decision-making and patient stratification, Onclara™ IO for predicting immunotherapy response and 12-month overall survival in PD-L1-High metastatic non-small cell lung cancer, Lung Clinical Management (LCM) for treatment decisions, and Onclara™ Studio for cloud-based cohort and patient-level visualization.

The company operates a dual-segment enterprise model targeting pharmaceutical companies for clinical trial licensing and risk-stratification services, and healthcare systems/oncology practices for clinical decision support once FDA clearance is secured. Onclara Evaluate has received FDA Breakthrough Device Designation and a planned 510(k) submission for Onclara IO is targeted for 2027. Validation partnerships span Pfizer, GSK, and Merck on the pharma side, with Flatiron Health as a real-world data partner and clinical collaborations across Stanford Medicine, City of Hope, MD Anderson, Emory Winship, Providence Health, Baylor Scott & White, and University of Rochester Medical Center. Revenue mechanics are primarily licensing/royalty-based for pharma trial applications, with a future subscription/recurring revenue stream anticipated for clinical decision support once FDA clearance is obtained. Pricing is not publicly disclosed and all products are currently investigational.

Onc.AI has raised approximately $33 million in total funding, including a $25 million Series A in January 2023 co-led by MassMutual and Action Potential Venture Capital and a $2 million NCI SBIR grant in October 2024. The leadership team is led by founders Akshay Nanduri (CEO) and Salmaan Ahmed (VP Software), with Lester Boeh as COO and Petr Jordan, PhD as CTO. The board is chaired by Jonathan Fleming and includes clinically credentialed directors and board observers, with a scientific and clinical advisory bench spanning oncology, immunotherapy, and AI/radiomics expertise. The company remains pre-commercial as of the most recent data, with revenue not publicly disclosed.

Onc.AI firmographics

Firmographics
Name
Onc.AI
Legal name
Onc.Ai, Inc.
Website
https://onc.ai
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Onc.AI is a clinical-stage digital health company that builds deep-learning imaging AI models applied to CT scans to predict immunotherapy response and support oncology clinical trial decisions, serving pharmaceutical companies and oncology practices with its Onclara platform.
Ownership category
akta.pro rank

Onc.AI industry classification

Industry
Product category
AI-Powered Clinical Decision Support for Oncology
NAICS
Medical and Diagnostic Laboratories (6215), Custom Computer Programming Services (541511)
SIC
Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAKAFAL
Thoracic (Lung) Oncology

Keywords

  • Oncology AI software
  • Imaging biomarkers
  • Clinical trial decision support
  • Deep learning radiomics
  • Immunotherapy response prediction

Where Onc.AI is headquartered

Location

Headquarters

HQ city
San Carlos
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Onc.AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharma Clinical Trial Solutions: Licensing or service fees from pharmaceutical companies for Onclara Evaluate to improve clinical trial design, patient stratification, and go/no-go decision-making in Phase IB and Phase II trials
  2. Clinical Decision Support: Potential future revenue from healthcare systems for Onclara IO clinical decision support tools for metastatic lung cancer patients treated with immunotherapy

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Onc.AI product offering

Product offering

Core offering

Onc.AI develops and sells the Onclara™ AI platform that applies deep learning to CT imaging to extract radiomic biomarkers and predict cancer treatment outcomes. Its core products include Onclara™ Evaluate for Phase IB/Phase II clinical trial decision-making (FDA Breakthrough designated) and Onclara™ IO for predicting response and outcomes in metastatic lung cancer patients receiving immunotherapy, sold to pharmaceutical companies and healthcare systems.

Product overview

Onc.AI offers the Onclara™ platform, a unified AI-powered system for oncology decision-making comprising multiple integrated products. The platform includes Onclara™ Evaluate (FDA Breakthrough designated) for clinical trial decision-making, Onclara™ IO for immunotherapy response prediction in metastatic lung cancer, Serial CTRS for NSCLC risk classification, and Lung Clinical Management for treatment decisions. Onclara™ Studio provides cloud-based visualization and analysis tools. The products leverage deep learning applied to CT imaging to extract radiomic biomarkers, tumor burden metrics, and body composition data to generate risk stratifications and survival predictions.

Differentiator

Problem solved

Functional benefit

Brands

  • Onclara™: Market-leading oncology real-world dataset platform that trains predictive and prognostic AI models for clinical decision-making in cancer treatment.
  • Onclara™ Evaluate
  • Onclara™ IO
  • Onclara™ Studio

Products and services

  • Onclara Platform Core AI platform that leverages a market-leading oncology real-world dataset to train predictive and prognostic AI models for oncology clinical trials and clinical practice; provides the infrastructure for Onclara Evaluate, Onclara IO, Serial CTRS, LCM, and Onclara Studio.
  • Onclara Evaluate AI-powered clinical decision support tool that improves Phase IB/Phase II clinical trial decision-making for pharmaceutical companies; uses deep learning to identify highest-risk patients and provide calibrated probability of achieving 12-month overall survival. FDA Breakthrough Device Designated. Sold to enterprise pharma companies.
  • Onclara IO AI-based CT imaging biomarker that predicts response and outcomes for metastatic lung cancer patients treated with immunotherapy; externally validated on Flatiron Health data for PD-L1-High metastatic non-small cell lung cancer. Targets healthcare systems and oncology clinical practice.
  • Onclara Studio Cloud-based platform providing intuitive visual and tabular outputs for immediate review or biostatistical analysis; supports secure CT scan upload and displays cohort-level analysis (Kaplan-Meier curves), patient-level tumor burden analysis, and body composition analysis. Sold to enterprise pharma companies and clinical users.
  • Serial CTRS (Serial CT Response Score) Deep learning model that classifies non-small cell lung cancer patients into risk groups; outperforms RECIST 1.1 in predicting overall survival in metastatic NSCLC patients treated with PD-1 immunotherapy. FDA Breakthrough Device Designated. Sold to pharmaceutical companies for clinical trial applications.
  • Lung Clinical Management (LCM) AI-driven tool for informing treatment decision-making for metastatic lung cancer patients treated with immunotherapy; validated on Pfizer clinical trial data and real-world datasets. Targets oncologists and healthcare providers.

Quantifiable outcome

  • Onclara IO High patients achieved median overall survival of 484 days vs 155 days for Onclara IO Low patients in PD-L1-High metastatic NSCLC (validated on Flatiron Health data, n=205)
  • +2 more outcomes

Companies that use Onc.AI

Customer profile

Named customers11 records

Segments2 records

Ideal customer profiles2 records

Onc.AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Onc.AI partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and supporting.

  • PfizercoreStrategic or Co-development PartnerClinical validation partner; Onc.AI models validated on Pfizer clinical trial data including LCM validation and Serial CTRS validation on Pfizer trials; ongoing collaboration for AI-driven clinical decision support
  • GSKcoreStrategic or Co-development PartnerClinical validation partner; Serial CTRS validated on GSK GARNET NSCLC cohort; collaboration for clinical development of AI biomarkers in oncology
  • MercksupportingStrategic or Co-development PartnerPharmaceutical partner for clinical AI solutions and potential validation studies
  • Flatiron HealthcoreTechnology or IntegrationReal-world data provider for external validation of Onc.AI models; provided retrospective cohort of 205 patients for Onclara IO validation; leading oncology data and analytics company
  • University of Rochester Medical CentersupportingStrategic or Co-development PartnerClinical validation partner; LCM clinical utility retrospective chart review study
  • Baylor Scott & WhitesupportingStrategic or Co-development PartnerClinical partner for validation studies and real-world data collaboration
  • Providence HealthsupportingStrategic or Co-development PartnerClinical partner for validation studies and healthcare system collaboration
  • City of HopesupportingStrategic or Co-development PartnerClinical partner for validation studies; comprehensive cancer center
  • UT Health San Antonio MD Anderson Cancer CentersupportingStrategic or Co-development PartnerClinical partner for validation studies; NCI-designated cancer center
  • Emory Winship Cancer InstitutesupportingStrategic or Co-development PartnerClinical partner for validation studies; NCI-designated cancer center
  • Stanford MedicinesupportingStrategic or Co-development PartnerClinical partner for validation studies and academic research collaboration

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Onc.AI competitors and assessment

Company assessment

Broad incumbents

  • Siemens Healthineers: Medical imaging vendor with AI-augmented CT and radiology software portfolios. Broad incumbent competitor that distributes imaging AI through its installed CT base and enterprise imaging platform.
  • GE HealthCare: Global medical imaging and diagnostics incumbent with growing AI/radiomics offerings embedded in CT and PACS workflows. A broader incumbent that can bundle competing imaging AI into its installed base.
  • Tempus Labs: Large oncology AI and data platform combining molecular profiling, imaging, and clinical data to support pharma R&D and clinical decision support. Broader portfolio than Onc.AI but overlaps in AI-driven oncology decision-making.

Others

  • Flatiron Health (Roche): Oncology real-world data and EHR company (Roche subsidiary) and Onc.AI's external validation partner for Onclara IO. Comparable as an oncology data/AI ecosystem participant, though primarily an enabling data partner rather than a direct imaging-AI competitor.

Direct peers

  • SOPHiA Genetics: AI-driven clinical decision support platform for genomic and imaging data used by hospitals and pharma. Comparable as a multimodal AI clinical decision support vendor serving both clinical practice and pharma/biotech.
  • Median Technologies: Provides imaging AI and radiomics solutions for oncology clinical trials and patient management. Closely comparable as an imaging-AI vendor targeting pharma trial design and oncology decision support.
  • Owkin: AI biotech company building prognostic and predictive biomarkers from real-world patient data for pharma R&D and clinical decision support across oncology. Comparable business model of AI biomarkers sold into pharma and provider workflows.
  • Artera (formerly ArteraAI): Develops AI-derived biomarkers from pathology and clinical data to personalize oncology treatment decisions, including for prostate cancer. Directly comparable as an AI biomarker company selling into both pharma clinical trials and clinical decision support.

Emerging players

  • PathAI: AI-powered pathology platform supporting pharma biomarker development and clinical diagnostics. Comparable AI-for-oncology business model serving pharma R&D and clinical workflows, focused on pathology rather than radiology.
  • Paige.AI: AI for digital pathology in oncology, including FDA-authorized products. Comparable as an AI oncology company selling into pharma and pathology labs, but with a different primary modality (pathology vs CT imaging).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Onc.AI social profiles

Digital presence

Onc.AI compliance and trust

Trust signal

Compliance1 record

Onc.AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Onc.AI leadership team

Management profile

Number of profiles

Profiles16 records

Onc.AI funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Onc.AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Onc.AI

What does Onc.AI do?

Onc.AI develops and sells the Onclara™ AI platform that applies deep learning to CT imaging to extract radiomic biomarkers and predict cancer treatment outcomes. Its core products include Onclara™ Evaluate for Phase IB/Phase II clinical trial decision-making (FDA Breakthrough designated) and Onclara™ IO for predicting response and outcomes in metastatic lung cancer patients receiving immunotherapy, sold to pharmaceutical companies and healthcare systems.

Is Onc.AI a public or private company?

Onc.AI is a private company. It is classified as venture growth investor backed and is currently operating.

When was Onc.AI founded?

Onc.AI was founded in 2020. It employs 11 to 50 people.

Where is Onc.AI based?

Onc.AI is headquartered in San Carlos, United States, in the North America region.

How does Onc.AI make money?

Two revenue lines are on record. Pharma Clinical Trial Solutions are the primary driver. The others are clinical Decision Support.

Who are Onc.AI's main competitors?

Broad incumbents on record are Siemens Healthineers, GE HealthCare and Tempus Labs. Flatiron Health (Roche) is listed as an others. Direct peers are SOPHiA Genetics, Median Technologies, Owkin and Artera (formerly ArteraAI). Emerging players are PathAI and Paige.AI.

Does Onc.AI have an API?

No public API is recorded for Onc.AI.

What industry is Onc.AI in?

Onc.AI's product category is AI-Powered Clinical Decision Support for Oncology. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLACAGAH, Oncology Pathways & Precision Medicine Decision Support. Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogOnc.AI Announces Positive External Validation of Onclara IO, a CT Imaging AI Biomarker for First-Line Immunotherapy in PD-L1-High Metastatic Non-Small Cell Lung CancerOnc.AI announced positive external validation results for Onclara IO, an AI-based CT imaging biomarker for PD-L1-High metastatic non-small cell lung cancer patients receiving first-line immunotherapy, with findings to be presented at ASCO 2026. In a retrospective cohort of 205 patients validated on Flatiron Health data, Onclara IO High patients achieved a median overall survival of 484 days versus 155 days for Onclara IO Low patients, demonstrating significant survival stratification beyond PD-L1 testing alone. The company expects to submit Onclara IO for FDA clearance as a software-as-medical-device in 2027.openPR.comFuture Perspectives: Key Trends Shaping the Cancer Clinical Decision Tools Market Until 2030The Business Research Company published a market report projecting the global cancer clinical decision tools market will reach $0.88 billion by 2030, growing at a 10.2% CAGR, driven by AI-powered tools, genomic data integration, and increased cancer screening efforts. In April 2025, RadNet Inc. acquired iCAD, Inc. for approximately $103 million through its DeepHealth subsidiary to accelerate AI-powered breast cancer detection by integrating iCAD's imaging and risk evaluation technologies. In February 2025, Onc.AI received FDA Breakthrough Device Designation for its Serial CTRS solution, an AI-driven tool that classifies non-small cell lung cancer patients into risk groups using deep learning algorithms.OncOnc.ai : AI-powered technology bringing clarity to cancer treatmentOnc.ai is developing a pipeline of AI models to advance precision oncology by leveraging real-world oncology datasets. The company's initial products aim to predict clinical outcomes in metastatic lung cancer to support pharmaceutical development and medical decision-making, with FDA approval pending.Business Wire BlogOnc.AI Awarded FDA Breakthrough Device Designation for Serial CT Response Score Deep Learning ModelOnc.AI received FDA Breakthrough Device Designation for its Serial CTRS AI model, which analyzes CT scans to stratify patients into high- or low-mortality risk categories. The model outperformed RECIST 1.1 in predicting overall survival for immunotherapy patients, and Onc.AI plans to use it for drug development and clinical trials.Business Wire BlogOnc.AI Awarded $2 Million National Cancer Institute Grant to Advance AI-based Clinical Decision Support for Metastatic NSCLCOnc.AI received a $2 million NCI SBIR grant to develop and validate its AI-based clinical decision support tool for metastatic non-small cell lung cancer. The grant funds a multi-institutional prospective study, building on prior ASCO results showing the tool's potential in predicting progression-free survival.Business Wire BlogOnc.AI to Present Collaboration Results Demonstrating Immunotherapy Response Prediction Using a Radiomic Signature in Late-Stage Lung CancerOnc.AI will present collaboration results at ASCO 2024 showing its radiomic signature predicts immunotherapy response in metastatic lung cancer. The model achieved a PFS hazard ratio of 0.30 and OS hazard ratio of 0.29 in a Pfizer clinical trial. The presentation is scheduled for June 1, 2024.CoveragerMassMutual backs Onc.AIOnc.AI has closed a $25 million Series A financing round co-led by MassMutual and Action Potential Venture Capital, with participation from Life Extension Ventures and existing investors. The company plans to use the proceeds to achieve regulatory milestones for its first lung cancer product and support research collaborations with global pharmaceutical leaders.Financial PostOnc.AI Raises $25 Million Series A Financing Co-Led by MassMutual and Action Potential Venture CapitalOnc.AI, a medical technology company developing digital clinical management solutions for immuno-oncology, has closed a $25 million Series A financing round co-led by MassMutual and Action Potential Venture Capital. The funding will support the commercialization of its first product targeting lung cancer and facilitate research collaborations with global pharmaceutical leaders. Key investors from the round, including representatives from MassMutual and Action Potential Venture Capital, have joined Onc.AI's Board of Directors.Venture Capital Access OnlineOnc.AI Raises $25 Million Series A Financing Co-Led by MassMutual and Action Potential Venture CapitalOnc.AI has closed a $25 million Series A financing round co-led by MassMutual and Action Potential Venture Capital to support the commercialization of its digital clinical management solution for immuno-oncology. The funding will be used to achieve regulatory milestones for a lung cancer product and expand research collaborations with pharmaceutical leaders. Investors David Diaz-Casariego and Juan-Pablo Mas will join the Onc.AI Board of Directors.BeBeezOnc.AI Raises $25 Million Series A Financing Co-Led by MassMutual and Action Potential Venture CapitalOnc.AI, a medical technology company specializing in immuno-oncology solutions, has closed a $25 million Series A financing round co-led by MassMutual and Action Potential Venture Capital. The funds will be used to achieve regulatory milestones for commercializing its AI-driven clinical management platform in lung cancer and to support research collaborations with global pharmaceutical leaders. New investors MassMutual and APVC have joined Onc.AI's Board of Directors alongside existing backers.